you are viewing a single comment's thread.
sorry. meant per quarter.copaxone has sales in the billions per year.
I stand corrected. $907 million is the lastest quarterly sales figure for Teva's Copaxone. This quadruples the potential sales value for Monmenta's generic Copaxone. Thanks for catching that. These numbers are so huge it is sometimes hard to wrap my head around the full potential of MNTA.